An open‐label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)‐(–)‐O‐desmethylvenlafaxine and racemic O‐desmethylvenlafaxine
Abstract
SEP‐227162 [R(–)‐O‐desmethylvenlafaxine] is an enantiomer of the venlafaxine metabolite O‐desmethylvenlafaxine (ODV, Pristiq™, Wyeth). This study compared the serotonin transporter (SERT) occupancy achieved by SEP‐227162 and ODV, at daily doses of 25, 50, 100, and 150 mg using [11C]DASB positron emission tomography (PET). Sixteen healthy male subjects participated in one of four dose groups (N = 4 per group) during which they were administered two doses of the study drug (SEP‐227162 or ODV). For each study drug, total daily doses of 25, 50, 100, and150 mg were studied. Subjects underwent three PET scans with [11C]DASB. A baseline, off‐medication, scan was performed prior to dosing and a [11C]DASB PET scan was performed after 72 hr at each dose level. [11C]DASB binding potential (BPND) was calculated using the simplified reference tissue method. SERT occupancy was calculated as the change in BPND (ΔBPND) from baseline scan to the on‐medication scan relative to the baseline BPND value. SEP‐227162 and ODV significantly reduced regional distribution volumes and region BPND values in a dose‐dependent manner. Across all doses ODV produced significantly greater SERT occupancy than SEP‐227162 (ANOVA F = 21.8, df = 1,23, p < .001). The total daily dose required to provide 50% SERT occupancy was 24.8 mg for SEP‐227162 and 14.4 mg for ODV. In vitro data suggests a ratio of 3.3:1 for binding at human SERT for SEP‐227162 relative to ODV. Our study suggests a ratio of 1.7:1, highlighting the value of in vivo imaging in the drug development process.Keywords
Funding Information
- Sepracor, Inc.
This publication has 33 references indexed in Scilit:
- Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorderCurrent Medical Research and Opinion, 2008
- Desvenlafaxine Succinate Identifies Novel Antagonist Binding Determinants in the Human Norepinephrine TransporterThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Consensus Nomenclature for in vivo Imaging of Reversibly Binding RadioligandsJournal of Cerebral Blood Flow & Metabolism, 2007
- Differentiating antidepressants of the future: Efficacy and safetyPharmacology & Therapeutics, 2007
- Advances in functional and structural MR image analysis and implementation as FSLNeuroImage, 2004
- Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C]DASB PET Imaging StudyAmerican Journal of Psychiatry, 2001
- Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithmIEEE Transactions on Medical Imaging, 2001
- New, faster, image-based scatter correction for 3D PETIEEE Transactions on Nuclear Science, 2000
- Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State PrincipleJournal of Cerebral Blood Flow & Metabolism, 1995
- Measurement of Benzodiazepine Receptor Number and Affinity in Humans Using Tracer Kinetic Modeling, Positron Emission Tomography, and [11C]FlumazenilJournal of Cerebral Blood Flow & Metabolism, 1993